In vivo type II T-helper cells shift in schizophrenia compared to sex- and age-matched healthy controls

European Journal of Psychiatry

Volumn 25, Issue 4, 2011, Pages 192-204

  Chiang, Sonnig Sue Whei ^a,b   Riedel, Michael ^a,b   Gruber, Rudolf ^a,b   Müller, Norbert ^a,b   Schwarz, Markus ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b NATIONAL CENTRAL UNIVERSITY   (Taiwan)

Author keywords

Cytokine; IFN gamma; IL 10; IL 4; Schizophrenia; Th2

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMAN; IN VIVO STUDY; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANK SUM TEST; SCHIZOPHRENIA; SEX DIFFERENCE; TH1 TH2 BALANCE; TH2 CELL;

EID: 84857508419     PISSN: 02136163     EISSN: None     Source Type: Journal    
DOI: 10.4321/S0213-61632011000400002     Document Type: Article

References (84)

1. Muller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil M, Möller HJ, et al. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci 2004; 254(1): 14-22.
2. Dhiman N, Ovsyannikova IG, Howe RC, Ryan JE, Jacobson RM, Poland GA. Interleukin-4 induced by measles virus and measles-derived peptides as measured by IL-4 receptor-blocking ELISA. J Immunol Methods 2004; 287(1-2): 217-225.
3. Brown AS, Begg MD, Gravenstein S, Schaefer CA, Wyatt RJ, Bresnahan M, et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 2004; 61(8): 774-780.
4. Ebert T, Kotler M. Prenatal exposure to influenza and the risk of subsequent development of schizophrenia. Isr Med Assoc J 2005; 7(1): 35-38.
5. Brown AS, Vinogradov S, Kremen WS, Poole JH, Deicken RF, Penner JD, et al. Prenatal exposure to maternal infection and executive dysfunction in adult schizophrenia. Am J Psychiatry 2009; 166(6): 683-690.
6. Bot A, Rodrigo E, Wolfe T, Bot S, Von Herrath MG. Infection-triggered regulatory mechanisms override the role of STAT 4 in control of the immune response to influenza virus antigens. J Virol 2003; 77(10): 5794-5800.
7. Oran AE, Robinson HL. DNA vaccines: influenza virus challenge of a Th2/Tc2 immune response results in a Th2/Tc1 response in the lung. J Virol 2004; 78(8): 4376-4380.
8. Miller CH, Maher SG, Young HA. Clinical Use of Interferon-gamma. Ann N Y Acad Sci 2009; 1182: 69-79.
9. Hegazy AN, Peine M, Helmstetter C, Panse I, Fröhlich A, Bergthaler A, et al. Interferons direct Th2 cell reprogramming to generate a stable GATA-3(+)T-bet(+) cell subset with combined Th2 and Th1 cell functions. Immunity 2010; 32(1):116-128.
10. Tang Y, Liao C, Xu X, Song H, Shi S, Yang S. Th1/Th2 Cytokine profiles in G+/G-bacteremia in pediatric hematology/oncology patients. Pediatr Blood Cancer 2011 [Epub ahead of print].
11. Sun L, Yu G, Yang S, Zhang L. Effects of hydrocortisone on the differentiation of human T helper 2 cells. Scand J Immunol 2011; 73(3): 208-214.
12. Romagnani S. Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease. Int J Clin Lab Res 1991; 21(2):152-158.
13. Gattaz WF, Dalgalarrondo P, Schroder HC. Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected. Schizophr Res 1992; 6(3): 237-241.
14. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Wagner RL, Yolken RH. Maternal cytokine levels during pregnancy and adult psychosis. Brain Behav Immun 2001; 15(4):411-420.
15. Kim YK, Lee MS, Suh KY. Decreased interleukin-2 production in Korean schizophrenic patients. Biol Psychiatry 1998; 43(9): 701-704.
16. Kaminska T, Wysocka A, Marmurowska-Michalowska H, Dubas-Slemp H, Kandefer-Szerszen M. Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch Immunol Ther Exp (Warsz) 2001; 49(6): 439-445.
17. Xu HM, Wei J, Hemmings GP. Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia. Br J Psychiatry 1994; 164(2):251-253.
18. Barak V, Barak Y, Levine J, Nisman B, Roisman I. Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. J Basic Clin Physiol Pharmacol 1995; 6(1): 61-69.
19. Schattner A, Cori Y, Hahn T, Sirota P. No evidence for autoimmunity in schizophrenia. J Autoimmun 1996; 9(5):661-666.
20. Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kühn M, Schuld A, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999; 33(5):407-418.
21. Erbagci AB, Herken H, Koyluoglu O, Yilmaz N, Tarakcioglu M. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm 2001; 10(3):109-115.
22. Schmitt A, Bertsch T, Tost H, Bergmann A, Henning U, Klimke A, et al. Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. Neuropsychiatr Dis Treat 2005; 1(2):171-177.
23. Coelho FM, Reis HJ, Nicolato R, Romano-Silva MA, Teixeira MM, Bauer ME, et al. Increased serum levels of inflammatory markers in chronic institutionalized patients with schizophrenia. Neuroimmunomodulation 2008; 15(2): 140-144.
24. O'Brien SM, Scully P, Dinan TG. Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Res 2008; 160(3):256-262.
25. Becker D, Kritschmann E, Floru S, Shlomo-David Y, Gotlieb-Stematsky T. Serum interferon in first psychotic attack. Br J Psychiatry 1990; 157:136-138.
26. Kim DJ, Kim W, Yoon SJ, Go HJ, Choi BM, Jun TY, et al. Effect of risperidone on serum cytokines. Int J Neurosci 2001; 111(1-2):11-19.
27. Barry S, Clarke G, Scully P, Dinan TG. Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. J Psychopharmacol 2009; 23(3): 287-294.
28. Rothermundt M, Arolt V, Leadbeater J, Peters M, Rudolf S, Kirchner H. Cytokine production in unmedicated and treated schizophrenic patients. Neuroreport 2000; 11(15):3385-3388.
29. Arolt V, Rothermundt M, Wandinger KP, Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry 2000; 5(2):150-158.
30. Rothermundt M, Arolt V, Weitzsch C, Eckhoff D, Kirchner H. Immunological dysfunction in schizophrenia: a systematic approach. Neuropsychobiology 1998; 37(4): 186-193.
31. Arolt V, Weitzsch C, Wilke I, Nolte A, Pinnow M, Rothermundt M, et al. Production of interferon-gamma in families with multiple occurrence of schizophrenia. Psychiatry Res 1997; 66(2-3):145-152.
32. Wilke I, Arolt V, Rothermundt M, Weitzsch C, Hornberg M, Kirchner H. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1996; 246(5):279-284.
33. Hornberg M, Arolt V, Wilke I, Kruse A, Kirchner H. Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia. Schizophr Res 1995; 15(3):237-242.
34. Katila H, Cantell K, Hirvonen S, Rimon R. Production of interferon-alpha and gamma by leukocytes from patients with schizophrenia. Schizophr Res 1989; 2(4-5):361-365.
35. Moises HW, Schindler L, Leroux M, Kirchner H. Decreased production of interferon alpha and interferon gamma in leucocyte cultures of schizophrenic patients. Acta Psychiatr Scand 1985; 72(1):45-50.
36. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008; 63(8):801-808.
37. Garver DL, Tamas RL, Holcomb JA. Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology 2003; 28(8):1515-1520.
38. Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 2002; 57(2-3):247-258.
39. van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK. Elevated interleukin-6 in schizophrenia. Psychiatry Res 1999; 87(2-3):129-136.
40. Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 1998; 32(1):9-15.
41. Naudin J, Capo C, Giusano B, Mege JL, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophr Res 1997; 26(2-3):227-233.
42. Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Riemann D, Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997; 247(4):228-233.
43. Naudin J, Mege JL, Azorin JM, Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophr Res 1996; 20(3):269-273.
44. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 1995; 29(2):141-152.
45. Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994; 89(5):346-351.
46. Shintani F, Kanba S, Maruo N, Nakaki T, Nibuya M, Suzuki E, et al. Serum interleukin-6 in schizophrenic patients. Life Sci 1991; 49(9):661-664.
47. Muller N, Riedel M, Gruber R, Ackenheil M, Schwarz MJ. The immune system and schizophrenia. An integrative view. Ann N Y Acad Sci 2000; 917: 456-467.
48. Schwarz MJ, Chiang S, Muller N, Ackenheil M. Thelper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav Immun 2001; 15(4):340-370.
49. Schwarz MJ, Muller N, Riedel M, Ackenheil M. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 2001; 56(4):483-486.
50. Zhou X, Schmidtke P, Zepp F, Meyer CU. Boosting interleukin-10 production: therapeutic effects and mechanisms. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5(4):465-475.
51. O'Garra A, Murphy K. Role of cytokines in determining T-lymphocyte function. Curr Opin Immunol 1994; 6(3):458-466.
52. Donckier V, Abramowicz D, Bruyns C, Florquin S, Vanderhaeghen ML, Amraoui Z, et al. IFN-gamma prevents Th2 cell-mediated pathology after neonatal injection of semiallogenic spleen cells in mice. J Immunol 1994; 153(6):2361-2368.
53. Abehsira-Amar O, Gibert M, Joliy M, Theze J, Jankovic DL. IL-4 plays a dominant role in the differential development of Tho into Th1 and Th2 cells. J Immunol 1992; 148(12):3820-3829.
54. Scott P. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J Immunol 1991; 147(9):3149-3155.
55. Wagner B, Burton A, Ainsworth D. Interferongamma, interleukin-4 and interleukin-10 production by T helper cells reveals intact Th1 and regulatory TR1 cell activation and a delay of the Th2 cell response in equine neonates and foals. Vet Res 2010;41(4):47.
56. Avgustin B, Wraber B, Tavcar R. Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. Croat Med J 2005; 46(2):268-274.
57. Kim YK, Myint AM, Lee BH, Han CS, Lee HJ, Kim DJ, et al. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28(7):1129-1134.
58. Jensen KD, Sercarz EE, Gabaglia CR. Altered peptide ligands can modify the Th2 T cell response to the immunodominant 161-175 peptide of LACK (Leishmania homolog for the receptor of activated C kinase). Mol Immunol 2009; 46(3):366-374.
59. Avery PR, Hoover EA. Gamma interferon/interleukin 10 balance in tissue lymphocytes correlates with down modulation of mucosal feline immunodeficiency virus infection. J Virol 2004; 78(8):4011-4019.
60. Watanabe Y, Nunokawa A, Shibuya M, Kaneko N, Nawa H, Someya T. Association study of interleukin 2 (IL2) and IL4 with schizophrenia in a Japanese population. Eur Arch Psychiatry Clin Neurosci 2008; 258(7):422-427.
61. World Health Organization. The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnosis guidelines. Geneva 1994.
62. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Press; 1994.
63. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988; 23(1):99-110.
64. Guy W (Ed.). ECDEU Assessment Manual for Psychopharmacology. Rockville, Maryland: Department of Health, Education, and Welfare; 1976.
65. Garcia-Miss Mdel R, Perez-Mutul J, Lopez-Canul B, Solís-Rodríguez F, Puga-Machado L, Oxté-Cabrera A, et al. Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia. J Psychiatr Res 2010; 44(7):441-446.
66. Nunes SO, Matsuo T, Kaminami MS, Watanabe MA, Reiche EM, Itano EN. An autoimmune or an inflammatory process in patients with schizophrenia, schizoaffective disorder, and in their biological relatives. Schizophr Res 2006; 84(1):180-182.
67. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Changes in serum interleukin-2,-6, and-8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry 2004; 65(7):940-947.
68. Zhang X, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 2002; 57(2-3):247-258.
69. Akiyama K. Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr Res 1999; 37(1):97-106.
70. Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B. Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 2009; 59(2):123-129.
71. Baker I, Masserano J, Wyatt RJ. Serum cytokine concentrations in patients with schizophrenia. Schizophr Res 1996; 20(1-2):199-203.
72. Trenerry MK, Della Gatta PA, Larsen AE, Garnham AP, Cameron-Smith D. Impact of resistance exercise training on interleukin-6 and JAK/STAT in young men. Muscle Nerve 2011; 43(3):385-392.
73. Freudenreich O, Brockman MA, Henderson DC, Evins AE, Fan X, Walsh JP, et al. Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR). Psychiatry Res 2010; 176(2-3):99-102.
74. Zhang XY, Zhou DF, Qi LY, Chen S, Cao LY, Chen da C, et al. Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopat ho-logy and response to antipsychotics. Psychopharmacology (Berl) 2009; 204(1):177-184.
75. Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 2008; 173(3):600-609.
76. Mouton PR, Kelley-Bell B, Tweedie D, Spangler EL, Perez E, Carlson OD, et al. The effects of age and lipopolysaccharide (LPS)-mediated peripheral inflammation on numbers of central catecholaminergic neurons. Neurobiol Aging 2010 [Epub ahead of print].
77. Shamsi S, Lau A, Lencz T, Burdick KE, DeRosse P, Brenner R, et al. Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res 2011; 126(1-3):257-264.
78. Ganguli R, Brar JS, Chengappa KR, DeLeo M, Yang ZW, Shurin G, et al. Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms. Arch Gen Psychiatry 1995; 52(8):668-672.
79. Bresee C, Rapaport MH. Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia. Int J Neuropsychopharmacol 2009; 12(6):861-865.
80. Martin JT. Sexual dimorphism in immune function: the role of prenatal exposure to androgens and estrogens. Eur J Pharmacol 2000; 405(1-3): 251-261.
81. Giron-Gonzalez JA, Moral FJ, Elvira J, García-Gil D, Guerrero F, Gavilán I, et al. Consistent production of a higher TH1:TH2 cytokine ratio by stimulated T cells in men compared with women. Eur J Endocrinol 2000; 143(1):31-36.
82. Gabbay V, Klein RG, Alonso CM, Babb JS, Nishawala M, De Jesus G, et al. Immune system dysregulation in adolescent major depressive disorder. J Affect Disord 2009; 115(1-2):177-182.
83. Fink G, Sumner BE, Rosie R, Grace O, Quinn JP. Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol Neurobiol 1996; 16(3):325-344.
84. Ko YH, Lew YM, Jung SW, Joe SH, Lee CH, Jung HG, et al. Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2008; 28(4):375-383.